HAMP and acute kidney injury: Ongoing clinical trials are assessing the potential applications of hepcidin agonists across a range of clinical conditions.[106] Conversely, the delivery of hepcidin is viewed as a prospective treatment approach for preventing and managing AKI within intensive care units.[107]